Amyris - AMRS Stock Forecast, Price & News

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of Amyris in a research report on Friday, June 24th. They issued a "neutral" rating for the company. Roth Capital downgraded Amyris from a "buy" rating to a "neutral" rating in a report on Wednesday. Finally, Piper Sandler began coverage on Amyris in a report on Wednesday, May 25th. They set a "neutral" rating and a $2.50 price target on the stock.

Amyris Stock Up 41.9 %

Amyris stock opened at $3.25 on Thursday. Amyris has a 1 year low of $1.47 and a 1 year high of $16.31. The business has a 50-day moving average of $2.05 and a 200-day moving average of $3.27. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.46 and a current ratio of 1.77.

Amyris (NASDAQ:AMRS - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $65.20 million during the quarter, compared to analyst estimates of $81.53 million. During the same period in the previous year, the company earned ($0.16) EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Amyris will post -1.07 EPS for the current year.

Insider Activity at Amyris

In other Amyris news, insider Nicole Kelsey sold 94,033 shares of the company's stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $1.80, for a total value of $169,259.40. Following the transaction, the insider now directly owns 63,333 shares of the company's stock, valued at approximately $113,999.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Nicole Kelsey sold 94,033 shares of the stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $1.80, for a total value of $169,259.40. Following the completion of the transaction, the insider now owns 63,333 shares of the company's stock, valued at approximately $113,999.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Hermanus Kieftenbeld sold 34,905 shares of the business's stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $2.34, for a total transaction of $81,677.70. Following the completion of the transaction, the chief financial officer now owns 266,655 shares in the company, valued at approximately $623,972.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 199,225 shares of company stock worth $403,182. Company insiders own 33.80% of the company's stock.